Literature DB >> 19247299

Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19247299     DOI： 10.1038/nrd2841

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

Authors:  Miguel L Stein; Margaret H Collins; Joyce M Villanueva; Jonathan P Kushner; Philip E Putnam; Bridget K Buckmeier; Alexandra H Filipovich; Amal H Assa'ad; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2006-11-07       Impact factor: 10.793
  1 in total
  1 in total

1.  Deal watch: Harnessing creative risk sharing.

Authors:  Tibor Papp
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.